TABLE 2. Estimated vaccination coverage by age 24 months* among children born during 2019–2020,^† by selected vaccines and doses and health insurance status^§ — National Immunization Survey-Child, United States, 2020–2022.

Vaccine/Dose	Health insurance status, % (95% CI)
	Private only (Ref) n = 15,668	Any Medicaid n = 9,682	Other insurance n = 1,961	Uninsured n = 422
DTaP¶
≥3 doses	96.3 (95.7–96.9)	92.2 (91.1–93.2)**	92.1 (89.5–94.3)**	80.4 (72.7–87.1)**
≥4 doses	87.3 (86.1–88.4)	76.6 (74.8–78.3)**	76.3 (72.3–80.1)**	61.3 (52.3–70.4)**
Poliovirus (≥3 doses)	95.6 (94.9–96.2)	91.3 (90.1–92.3)**	91.6 (88.9–93.8)**	80.0 (72.2–86.9)**
MMR (≥1 dose)††	94.6 (93.9–95.3)	89.6 (88.4–90.7)**	88.9 (85.7–91.6)**	78.3 (70.1–85.6)**
Hib§§
Primary series	95.7 (95.0–96.4)	91.9 (90.9–92.9)**	91.8 (89.3–94.0)**	78.8 (71.0–85.8)**
Full series	84.4 (83.2–85.6)	75.1 (73.3–76.9)**	76.7 (72.9–80.3)**	61.9 (53.1–70.8)**
HepB
Birth dose¶¶	83.0 (81.8–84.2)	81.6 (80.1–83.0)	74.9 (70.8–78.5)**	63.7 (53.7–72.7)**
≥3 doses	93.7 (92.9–94.5)	91.3 (90.2–92.3)**	90.8 (88.2–93.1)**	76.2 (68.1–83.6)**
VAR (≥1 dose)††	94.0 (93.2–94.8)	89.5 (88.2–90.6)**	87.7 (84.4–90.5)**	76.5 (68.5–83.8)**
PCV
≥3 doses	95.6 (94.8–96.3)	91.0 (89.8–92.1)**	91.3 (88.6–93.5)**	79.9 (72.0–86.8)**
≥4 doses	89.3 (88.3–90.4)	78.1 (76.3–79.8)**	79.3 (75.7–82.8)**	55.3 (46.2–64.8)**
HepA
≥1 dose	91.2 (90.3–92.1)	86.7 (85.3–87.9)**	86.0 (82.8–88.9)**	72.3 (63.5–80.5)**
≥2 doses***	51.9 (50.3–53.5)	44.7 (42.7–46.7)**	43.9 (39.6–48.4)**	—†††
≥2 doses (by age 35 mos)***	85.4 (83.7–87.0)	76.3 (73.5–78.9)**	75.4 (69.7–80.7)**	—†††
Rotavirus (by age 8 mos)§§§	84.1 (82.9–85.3)	71.2 (69.5–72.9)**	72.9 (68.5–76.9)**	52.0 (42.6–61.2)**
Influenza (≥2 doses)¶¶¶	75.5 (74.1–76.9)	49.2 (47.3–51.2)**	61.4 (57.1–65.6)**	37.8 (29.4–47.6)**
Combined seven-vaccine series****	76.6 (75.1–78.0)	63.6 (61.6–65.5)**	66.2 (62.0–70.4)**	42.5 (33.9–52.3)**
No vaccinations	0.6 (0.5–0.8)	1.2 (0.8–1.5)**	0.8 (0.5–1.2)	6.0 (3.4–9.5)**

Abbreviations: DTaP = diphtheria and tetanus toxoids and acellular pertussis vaccine; HepA = hepatitis A vaccine; HepB = hepatitis B vaccine; Hib = Haemophilus influenzae type b conjugate vaccine; MMR = measles, mumps, and rubella vaccine; PCV = pneumococcal conjugate vaccine; Ref = referent group; VAR = varicella vaccine.

* Includes vaccinations received by age 24 months, except for the HepB birth dose, rotavirus vaccination, and ≥2 HepA doses by age 35 months. For all vaccines except the HepB birth dose and rotavirus vaccination, the Kaplan-Meier method was used to estimate vaccination coverage to account for children whose vaccination history was ascertained before age 24 months (35 months for ≥2 HepA doses).

^† Data for the 2019 birth year are from survey years 2020, 2021, and 2022; data for the 2020 birth year are considered preliminary and are from survey years 2021 and 2022 (data from survey year 2023 are not yet available).

^§ Children’s health insurance status was reported by parent or guardian. “Other insurance” includes the Children’s Health Insurance Program, military insurance, coverage through the Indian Health Service, and any other type of health insurance not mentioned elsewhere.

^¶ Includes children who might have been vaccinated with diphtheria and tetanus toxoids vaccine or diphtheria, tetanus toxoids, and pertussis vaccine.

** Statistically significant (p<0.05) difference compared with the Ref.

^†† Includes children who might have been vaccinated with MMR and VAR combination vaccine.

^§§ Hib primary series: receipt of ≥2 or ≥3 doses, depending on product type received; full series: primary series and booster dose, which includes receipt of ≥3 or ≥4 doses, depending on product type received.

^¶¶ One dose HepB administered from birth through age 3 days.

*** Before 2020, the first Hep A dose was recommended at age 12–23 months, with the second dose given 6–18 months after the first, depending upon the product type received. In 2020, recommendation was revised to 2 doses between ages 12 and 23 months, ≥6 months apart. Because children in this analysis were vaccinated under both recommendations, coverage estimates for both 24 months and 35 months are provided.

^††† Estimate was not available because the unweighted sample size for the denominator was <30, 95% CI half width divided by the estimate was >0.588, or 95% CI half-width was ≥10.

^§§§ Includes ≥2 doses of Rotarix monovalent rotavirus vaccine or ≥3 doses of RotaTeq pentavalent rotavirus vaccine; if any dose in the series is either RotaTeq or unknown, the default is to a 3-dose series. The maximum age for the final rotavirus dose is 8 months, 0 days.

^¶¶¶ Influenza vaccine doses must be ≥24 days apart (4 weeks with a 4-day grace period); doses could have been received during two influenza seasons.

**** The combined seven-vaccine series (4:3:1:3*:3:1:4) includes ≥4 doses of DTaP, ≥3 doses of poliovirus vaccine, ≥1 dose of measles-containing vaccine, the full series of Hib (≥3 or ≥4 doses, depending on product type), ≥3 doses of HepB, ≥1 dose of VAR, and ≥4 doses of PCV.